log therapy (leuprorelin) and chemotherapy (docetaxel) as well as long-term prednisone therapy (7.5 mg/day), but complained of severe bone pain despite significant analgesic treatment.
Examination. On examination we observed that the patient was adynamic and appeared anemic. He had an elevated temperature (38.5°C), signs of sinusitis, bilateral incomplete ophthalmoplegia, and no significant decrease of visual fields. No other neurological deficits were present. The patient underwent an emergency MR imaging study (Fig. 1) .
Laboratory studies confirmed the clinical impression of anemia (hemoglobin 8.6 g/dl, leukocytes 3.2 × 10 9 /L, thrombocytes 92 × 10 9 /L), and an elevated C-reactive protein level (150 mg/L). Endocrinological parameters on admission are shown in Table 1 .
Treatment Considerations. The patient was initially treated with antibiotics and erythrocyte transfusion. After an unsuccessful trial of high-dose dexamethasone therapy, we discussed the treatment options with the patient and his oncologist. Radiotherapy was not considered likely to be beneficial due to the already significant compression of the optic nerves and fear of further swelling. We therefore recommended a selective transsphenoidal removal of the pituitary tumor to indirectly decompress the nerves within the cavernous sinus. Furthermore, the additional resection of the anterior lobe of the pituitary gland was discussed as a palliative hormonal treatment for the prostate cancer, especially with respect to the patient's bone pain.
We decided upon this latter option because of the ad ditional palliative potential, particularly as the patient showed high-normal IGF-I and prolactin levels.
Operation. Written consent was obtained and the patient underwent ultra direct microscopic transnasal-transsphenoidal surgery through the right nostril in a semisitting position. Inflamed mucosa within the sphenoid sinus was removed, the floor of the sella was drilled with a diamond drill, and the carotid arteries were located within the cavernous sinus by means of a microDoppler device as previously described. 10, 18 The tumor was removed (by J.F.) and diagnosed as a regular pituitary adenoma by cytology and frozen sections. Afterward, a hypophysectomy with preservation of the posterior lobe as well as the stalk was performed (by D.K.L.) with visualization of both rims of the cavernous sinus, showing tumor tissue growing out of the cavernous sinus area. After appropriate hemostasis was achieved the sella was filled with muscle from the lateral portion of the rectus femoris muscle. Postoperative MR imaging verified the improvement of the intrasellar alterations (Fig. 2) .
Histological Findings. Histological investigation of the specimen revealed a highly vascularized epithelial tumor composed of polygonal, densely packed, mildly pleomorphic cells with round nuclei and prominent nucleoli and growing as a solid mass (Fig. 3) . The tumor cells were immunoreactive for FSH and LH ( Fig. 4a and b) , showed only low proliferative activity as determined by Ki 67 immunostaining ( Fig. 4c ) and did not stain for cytokeratin (Fig. 4d) . The tumor was diagnosed as a clinically non- 
* Values for cortisol are not reported because the patient was receiving long-term treatment with 7.5 mg prednisone daily. Abbreviations: ACTH = adrenocorticotropic hormone; hGH = human growth hormone; TSH = thyroid-stimulating hormone. secreting pituitary adenoma immune-reactive for LH and FSH. Within the adenoma, small, circumscribed nests of large pleomorphic cells with prominent nuclear polymorphism and conspicuous mitotic activity were identified (Fig. 3) . Approximately 80% of these tumor cells were labeled with Ki 67 antibodies (Fig. 4c) . The pleomorphic tumor cells showed weak immunoreactivity to antibodies against PSA (Fig. 4e) and stained strongly positive for cytokeratin (Fig. 4d) . Interestingly, most of these tumor cells were located within blood vessels, as determined by immunostaining for CD 34 (Fig. 4f) . Thus, the specimen comprised 2 different tumor entities, leading to the diagnosis of a metastasis of an adenocarcinoma of the prostate within a clinically nonsecreting pituitary adenoma.
Postoperative Course. After the surgery the patient re covered rapidly from the cavernous sinus syndrome. Ad ditionally, the severe generalized bone pain nearly re- solved, allowing a dramatic reduction of analgesia. The postoperative endocrinological parameters are shown in Table 1 . Prednisone therapy (7.5 mg/day) was continued, the patient was started on a low-dose levothyroxine therapy (50 μg/day). No testosterone-or hGH substitution therapy was considered. The posterior lobe function was preserved without signs of diabetes insipidus. The patient was discharged 10 days after surgery in improved physical condition and nearly pain free.
Because of ongoing disease, the ambulatory docetaxel chemotherapy was continued. However, the patient's health deteriorated further, resulting in readmission to the hospital because of anemia and septicemia. Despite antibiotic treatment the patient died 4 months after the transsphenoidal surgery. During the 4 months no further pain therapy was needed, and the patient remained nearly pain free.
Discussion
In 1972, Huggins and Hodges 12 first reported on the effects of castration on metastatic prostate cancer. In the following decades, castration by orchidectomy leading to androgen withdrawal became a standard treatment in prostate cancer. Other options of hormone treatment, such as estrogen therapy, were discovered and further developed. In 1948, Scott performed the first hypophysectomy in a patient with prostate cancer. The patient died, probably due to hypocortisolism (cortisone became available 1950). 30 In 1952, Luft et al.
19 be came the first au thors to re port a successful hypophysectomy. Scott and Schirmer 30 published a report on a series of 17 patients un dergoing hypophysectomy for prostate cancer. They concluded that patients who had ongoing disease (despite previously successful hormone treatment such as castration or estrogen therapy) and residual androgen production might benefit the most from hypophysectomy. In the following years, further studies were published with objective "remission" rates of 35-53%. An average survival time of 15.8 months (range 6-28 months, 34 patients) was reported, compared with 4 months in patients who had not undergone hypophysectomy. 23 Another therapeutical aspect of hypophysectomy in the treatment of prostate cancer is its effect on metastatic bone pain. In general, a success rate of up to 80% was reported for otherwise therapy-resistant bone pain in patients with metastatic disease. 15, 24 According to a current theory, androgen-independent tumor progression especially in bone metastases can be explained by a release of "survival factors" within the microenvironment of the metastasis-surrounding bone tissue, protecting the carcinoma cells from androgen ablation. 13 Frequently, the metastases grow, while the primary tumor site is stable.
14,28
In the decades following the introduction of GnRH analogs, surgical treatments such as adrenalectomy and hypophysectomy became nearly obsolete.
Unfortunately, prostate cancer cells only respond to androgen withdrawal for a limited time; the tumors eventually become androgen-independent. 27, 29 Other pituitary hormones, including prolactin, growth hormone, IGF-I, and possibly LH, are known to play an important role in prostate tissue. 26 Prolactin, for example, is important for proliferation as well as for differentiation of prostate tissue by stimulation of testicular steroid genesis and direct activation of 5-α-reductase in the prostate cells. 7, 11, 22 In 1990, Lobie et al. 16 discovered the expression of growth hormone receptors in prostate tissue. In recent years, animal studies have shown that IGF-I depletion leads to reduced prostate weight, 1 whereas in acromegaly prostate hyperplasia is commonly found and reversed by octreotide treatment. 6 Furthermore, increased IGF-I plasma levels seem to be positively correlated with prostate cancer. 4 The possible use of octreotide treatment in metastatic prostate cancer was discussed by Vainas in 2001. 33 Only recently, Koutsilieris et al.
14 published a clinical study on the use of octreotide in combination with dexamethasone and androgen ablation therapy in patients with androgen ablationrefractory metastatic prostate cancer. A partial response (identified by means of PSA decrease) was found in 60% of patients, stable disease was reported in 20%, and tumor progression was reported in 20%. All participating patients experienced a significant improvement of bone pain and performance.
Metastatic disease in the pituitary gland is an unusual complication of systemic cancer that rarely causes clinical symptoms; 21, 32 it has been reported in 0.14-2.81% of all brain metastases in autopsy series. 5, 20, 31 While breast and lung cancer are the most common sites of the primary tumor, 9,21 prostate carcinomas metastatic to the pituitary gland have also been observed. 8, 9, 17 Metastases to pituitary adenomas, however, are rare. To date, only 16 cases have been reported in the literature, 3 with only one tumor originating in the prostate.
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Conclusions
We are well aware that hypophysectomy for metastatic prostate cancer that is progressing despite state-of-the-art therapy represents only a palliative treatment. Nevertheless, even in patients without an additional pituitary adenoma and related neurological symptoms, the treatment offers potential benefits regarding survival time and pain control, if certain precautions are taken into account (for example, management of anemia, use of hydro cortisone replacement therapy). This case report may also lead to further ideas for additional endocrinological therapies in advanced stages of prostate cancer.
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